Mukherjee Nabanita, Schwan Josianna V, Fujita Mayumi, Norris David A, Shellman Yiqun G
Department of Dermatology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Department of Dermatology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA; Department of Veterans Affairs Medical Center, Dermatology Section, Denver, Colorado, USA.
J Invest Dermatol. 2015 Sep;135(9):2155-2161. doi: 10.1038/jid.2015.145. Epub 2015 May 7.
For the first time new treatments in melanoma have produced significant responses in advanced diseases, but 30-90% of melanoma patients do not respond or eventually relapse after the initial response to the current treatments. The resistance of these melanomas is likely due to tumor heterogeneity, which may be explained by models such as the stochastic, hierarchical, and phenotype-switching models. This review will discuss the recent advancements in targeting BCL-2 family members for cancer treatments, and how this approach can be applied as an alternative option to combat melanoma, and overcome melanoma relapse or resistance in current treatment regimens.
黑色素瘤的新疗法首次在晚期疾病中产生了显著疗效，但30%至90%的黑色素瘤患者对当前治疗无反应或在初始反应后最终复发。这些黑色素瘤的耐药性可能归因于肿瘤异质性，随机、分层和表型转换模型等模型或许可以解释这一现象。本综述将讨论靶向BCL-2家族成员进行癌症治疗的最新进展，以及该方法如何作为一种替代方案来对抗黑色素瘤，并克服当前治疗方案中的黑色素瘤复发或耐药问题。
